On February 20, 2025, Variational AI announced the successful completion of its US$5.5-million seed extension financing round led by Nimbus Synergies, with participation from Merck Global Health Innovation Fund, Quimby Investments, Threshold Impact and Defined Capital. Existing investors Flying Fish, A&E Investment and Nepenthe Capital participated in the round. Variational AI plans to use the funding to bring its technology to a broader market, helping biopharmaceutical companies design novel drugs faster and more efficiently.
Variational AI, based in Vancouver, British Columbia, is redefining the unit economics of drug discovery through the power of generative AI. They have developed EnkiTM, the industry-leading foundation model for small molecule drug discovery.
Osler, Hoskin & Harcourt LLP advised Variational AI with a team consisting of Mark Longo, Riley Graydon, Ian Morrison and Michelle Wong (Emerging and High Growth Companies).
Key Contact
Vancouver Managing Partner, Vancouver
Team
Associate, Emerging and High Growth Companies, Vancouver
Associate, Emerging and High Growth Companies, Vancouver
Associate, Emerging and High Growth Companies, Vancouver
